Abstract
Lipoxygenases (LOXs), cytochromes P450 (CYPs) and cyclooxygenases (COXs) catalyze peroxidation of unsaturated fatty acids. In humans they convert arachidonic acid into a variety of eicosanoids, which play a role in all inflammatory responses, cardiovascular and kidney diseases, Alzheimers, cancer and other ailments. Blocking one pathway can prompt the body to switch to the available alternatives. In contrast to CYP and COX, LOX has a non-heme iron co-factor. Several LOXs are produced or stress-induced in the human body. They share the same mechanism, but differ in sequence causing catalysis on the same substrate to be regio- and stereospecific. The action of 15-LOXs could be pro- or anti-inflammatory, and pro- or anticarcinogenic. Depending on the dose, LOXs inhibitors can induce or inhibit other oxygenases. Inhibition of these enzymes presents a great challenge in solving the problem of how to control their action and treat diseases, without causing severe side effects and maintaining/restoring a delicate equilibrium between them. Research on CYPs and COXs is more advanced, while studies of LOXs are lagging behind. This article presents a brief review about LOX structures and inhibition, their involvement in human diseases, and their interplay with other oxidoreductases.
Keywords: Lipoxygenase, fatty acids, inhibition, structure, NSAIDs, regulation of oxygenases, eicosanoids in human diseases
Current Enzyme Inhibition
Title: Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development
Volume: 3 Issue: 2
Author(s): Ewa Skrzypczak-Jankun, Joanna Chorostowska-Wynimko, Steven H. Selman and Jerzy Jankun
Affiliation:
Keywords: Lipoxygenase, fatty acids, inhibition, structure, NSAIDs, regulation of oxygenases, eicosanoids in human diseases
Abstract: Lipoxygenases (LOXs), cytochromes P450 (CYPs) and cyclooxygenases (COXs) catalyze peroxidation of unsaturated fatty acids. In humans they convert arachidonic acid into a variety of eicosanoids, which play a role in all inflammatory responses, cardiovascular and kidney diseases, Alzheimers, cancer and other ailments. Blocking one pathway can prompt the body to switch to the available alternatives. In contrast to CYP and COX, LOX has a non-heme iron co-factor. Several LOXs are produced or stress-induced in the human body. They share the same mechanism, but differ in sequence causing catalysis on the same substrate to be regio- and stereospecific. The action of 15-LOXs could be pro- or anti-inflammatory, and pro- or anticarcinogenic. Depending on the dose, LOXs inhibitors can induce or inhibit other oxygenases. Inhibition of these enzymes presents a great challenge in solving the problem of how to control their action and treat diseases, without causing severe side effects and maintaining/restoring a delicate equilibrium between them. Research on CYPs and COXs is more advanced, while studies of LOXs are lagging behind. This article presents a brief review about LOX structures and inhibition, their involvement in human diseases, and their interplay with other oxidoreductases.
Export Options
About this article
Cite this article as:
Skrzypczak-Jankun Ewa, Chorostowska-Wynimko Joanna, Selman H. Steven and Jankun Jerzy, Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development, Current Enzyme Inhibition 2007; 3 (2) . https://dx.doi.org/10.2174/157340807780598350
DOI https://dx.doi.org/10.2174/157340807780598350 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Neurogenesis as a New Target for the Development of Antidepressant Drugs
Current Pharmaceutical Design Abnormalities of Peptide Metabolism in Alzheimer Disease
Current Neurovascular Research Molecular Determinants of Fluoroquinolone Antibacterial Agents Pharmacokinetics
Current Clinical Pharmacology Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Meet Our Editorial Board Member
Current Neuropharmacology Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry The Influence of Hypothalamic Cytokine PRP on Protein Synthesis in Brain Subcellular Compartments in Crush Syndrome
Central Nervous System Agents in Medicinal Chemistry Nanotechnology can Provide Therapeutic Agent by Targeting Molecular Structures of SARS-CoV-2 (COVID-19): A Mini-Review
Letters in Drug Design & Discovery Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case
Current Psychiatry Reviews Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets Determination of Spatial and Temporal Distribution of Microglia by 230nm-High-Resolution, High-Throughput Automated Analysis Reveals Different Amyloid Plaque Populations in an APP/PS1 Mouse Model of Alzheimers Disease
Current Alzheimer Research Cholinesterases: Roles in the Brain During Health and Disease
Current Alzheimer Research Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs
Current Psychiatry Research and Reviews Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Therapeutic Prospects for the Prevention of Neurodegeneration in Huntingtons Disease and the Polyglutamine Repeat Disorders
Mini-Reviews in Medicinal Chemistry microRNAs in Autism Spectrum Disorders
Current Pharmaceutical Design Effectiveness of Gonadotropin Administration for Spermatogenesis Induction in Hypogonadotropic Hypogonadism: A Possible Role of Androgen Receptor CAG Repeat Polymorphism and Therapeutic Measures
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men.
CNS & Neurological Disorders - Drug Targets